Race Oncology Ltd (ASX:RAC) has appointed banking veteran Daniel Sharp as an independent non-executive director.
A former lawyer, Sharp has advised the boards of technology and healthcare-based organisations on global capital markets for more than 25 years.
He is currently a non-executive director of health informatics company Alcidion Group (ASX:ALC) Ltd and a non-executive director of dermatology-focused Botanix Pharmaceuticals Ltd (ASX:BOT).
Sharp is also a member of the investment committee of the Baker Heart and Diabetes Institute Foundation.
Broadening expertise pool
“On behalf of my fellow directors, I am delighted to welcome Danny Sharp to the board of Race,” company chair Dr John Cullity said.
“His appointment aligns with our focus on preparing the company for substantial engagement with commercial partners and institutional investors as we take forward our Three Pillar strategy. It also broadens our independent director pool and brings additional legal, financial and governance experience to the board,” he added.
Sharp holds a Bachelor of Economics and Law and is a Chartered Financial Analyst charter holder.
Race is a precision oncology company with a Phase 2/3 cancer drug called Zantrene®, a potent inhibitor of the Fatso/Fat mass and obesity-associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.
The company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.